SynPhNe, a medtech spin-off from Nanyang Technological University, Singapore (NTU Singapore), has secured $5 million in Series A funding from Event Horizon Technologies Pte Ltd, a member of the Nadathur Group.

SynPhNe said in a statement on Monday that the Series A funding will help propel the firm forward in its mission to revolutionize the field of stroke and neurological rehabilitation across Singapore, United States and India, among other countries.

It said the successful raising of Series A by the company is a testament to the potential impact of its technology on the global healthcare landscape, particularly in addressing the vast, yet largely untapped, market opportunity in the stroke and brain injury sector, estimated at $30 billion in the United States alone.

It also said the financial support will enable SynPhNe to expand its commercial partnerships, scale its operations in the US market, and further the development and commercial validation of its next-generation products and applications in related fields.

It is noted that its flagship product, SynPhNe, is a pioneering wearable solution that accelerates the rehabilitation of individuals recovering from strokes and patients battling brain injury, neurodevelopmental and neurodegenerative disorders.

This novel technology, which leverages a combination of neural feedback, gamification and data science, can offer a real-time “inside view” into patient rehabilitation and their progress, and can be easily tailored to meet the unique challenges faced by each individual.

According to the statement, the technology’s effectiveness is supported by an array of global patents, clinical trials, and publications, alongside a growing number of worldwide commercial patients who have benefitted from using the technology.

SynPhNe targets brain and muscle training simultaneously, addressing both physical and cognitive aspects of recovery which enhance independence.

It helps early-stage patients to reach higher levels of independence sooner and enables long- term patients to break out of recovery plateaus, aiding their return to independent living.

It is suitable for in-clinic as well as home settings in the continuum of care.

Patients can actively engage in their rehabilitation journey with real-time feedback.

It allows therapists to track progress in areas previously considered “invisible” and make more informed, personalized adjustments to their therapy plans in real-time.

SynPhNe has received acclaim for its life-changing impact, empowering individuals to regain and enhance mobility and cognitive function, ultimately impacting the overall performance and quality of life of patients and patient families.

SynPhNe is a deep tech spin-off company with licensed technologies from NTU and is incubated by NTUitive, the University’s innovation and enterprise company.

Over the years, it also benefitted from invaluable guidance and resources from the Singapore-MIT Alliance for Research and Technology (SMART).

The fundamental science and research upon which SynPhNe was based, was supported by the National Medical Research Council and National Research Foundation, Singapore.

In addition to research support, SynPhNe also had help from Enterprise Singapore, which has been pivotal in scaling SynPhNe’s reach beyond local shores, providing both pre-
commercial grant funding and essential market access support.

The support has helped SynPhNe to navigate the global market more effectively, bringing its revolutionary rehabilitation technology to more patients worldwide.

Nadathur is the family office of Nadathur S. Raghavan, Co-founder of Infosys.

The family office invests significant resources and holds concentrated stakes in promising, high-potential ventures at the forefront of science and technology innovation across diverse domains.

The Nadathur family office also builds and manages endowment-style multi-generational portfolios with mandates ranging from capital preservation to high growth.

They partner with fund managers, other family offices and institutional investors globally to invest across traditional as well as alternative asset classes.

Singapore’s Biorithm secures $3.5M in Series A funding co-led by Adaptive Capital Partners, SEEDS Capital